Company: ARWR
Filing Date: 2025-12-11
Form Type: S-3ASR
Source: 0001193125-25-314755
Chunk: 37

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-12-11
Form: S-3ASR
Chunk 37
---
500,000,000 is sold at that price, would increase our adjusted net tangible book value per share after the offering by $0.005 per share and the dilution in net tangible book value per share to new investors in this offering would remain at $6.89 per share, after deducting estimated offering expenses and commissions payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed offering price of $68.83 per share shown in the table above, assuming all of our common stock in the aggregate amount of $500,000,000 is sold at that price, would decrease our adjusted net tangible book value per share after the offering by $0.005 per share and would decrease the dilution in net tangible book value per share to new investors in this offering to $6.88 per share, after deducting estimated offering expenses and commissions payable by us. This information is supplied for illustrative purposes only. Unless we indicate otherwise, all information in this prospectus supplement is based on 135,702,000 shares of our common stock outstanding as of September 30, 2025, and excludes:

| • |     | 1,407,035 shares of our common stock subject to options outstanding as of September 30, 2025 under the 2013                                                                                      
 Plan, the 2021 Plan, the Inducement Plan and issued as inducement grants to new employees outside of our equity compensation plans having a weighted average exercise price of $28.90 per share; |

| • |     | 5,810,351 restricted stock units granted and outstanding as of September 30, 2025 under the 2013 Plan, 2021      
 Plan, Inducement Plan and issued as inducement grants to new employees outside of our equity compensation plans; |

S-9

| • |     | 2,378,770 shares reserved for issuance under the 2021 Plan; |

| • |     | 255,244 shares reserved for issuance under the Inducement Plan; and |

| • |     | 917,441 shares of common stock issuable upon the exercise of outstanding            
 pre-funded warrants at an exercise price of $0.001 per share (which do not expire). |

To the extent that outstanding options are exercised, or we issue other shares, investors purchasing shares in this offering could experience further dilution. In addition, we may choose to raise additional capital due to market conditions or